Genomix aims to make genome sequencing accessible and help eradicate age related diseases through advanced data science by indexing, correlating and linking the world's genomic, phenotypic, microbiomic and health data. Through our platform, individuals can access genome sequencing and researchers can access advanced data and predictive data models to drive more meaningful research outcomes.

Ageing remains the single biggest risk factor for virtually all diseases. If we understood ageing we could potentially eradicate all age related diseases through regenerative medicine. Furthermore, governments are increasingly under pressure to fund aged related health costs. Yet not enough research or progress is made in regenerative medicine. Data science plays a large role in this field, however health data is currently siloed and scattered. Genomix aims to link and map relationships between data sets to progress regenerative medicine....
Genomix aims to make genome sequencing accessible and help eradicate age related diseases through advanced data science by indexing, correlating and linking the world's genomic, phenotypic, microbiomic and health data. Through our platform, individuals can access genome sequencing and researchers can access advanced data and predictive data models to drive more meaningful research outcomes.

Ageing remains the single biggest risk factor for virtually all diseases. If we understood ageing we could potentially eradicate all age related diseases through regenerative medicine. Furthermore, governments are increasingly under pressure to fund aged related health costs. Yet not enough research or progress is made in regenerative medicine. Data science plays a large role in this field, however health data is currently siloed and scattered. Genomix aims to link and map relationships between data sets to progress regenerative medicine.
More information

Investors

INCUBATE Class 8 (Winter 2016)
Admin
INCUBATE Class 8 (Winter 2016) The leading startup accelerator program at the University of Sydney

Recommendations

Allen Smith

Neville Richards is an accomplished technologist with a passion in health and wellbeing. He has extensive experience bringing together robust scalable technical solutions to the most challenging problems. I am excited to see the platform Neville and Alyse are creating as I believe it can have wide reaching benefits across many aspects of healthcare.

Alexey Feigin Cofounder at Tapview

Alyse has both a very clear vision for using cutting-edge technological advances to improve human health, as well as the skills required for bringing the right people together to make it happen. I have seen firsthand that she is diligent in her market research and great at actively finding relevant experts and partnerships. I would endorse Alyse and Genomix for any startup accelerator program.

Kristina Craig Director, Head of Innovation Lab at KPMG Australia

Alyse is a visionary at heart with a great sense and awareness of cutting edge technology and innovation. Her passion for human longevity coupled with her entrepreneurial mindset, tenacity and ability to execute are second to none - I have no hesitation in recommending her and Genomix.

James Jansson Cofounder at Tapview

Alyse Sue is an individual committed to bettering human health and extending life through the use of technology. Her startup, Genomix, is a natural extension of her vision, putting technology into the hands of everyday people while pushing the underlying technology and research forward.

Nelson Lau

As a medical practitioner, I think the idea of the patient having more agency over their own genomic data and making it available in the marketplace to help facilitate research as well as being financially compensated for it opens up a whole range of opportunities for both the patient and the researchers. The fact that they can be followed up if they wish to and that they can also provide more detailed demographics including their gender and ethnicity means that the more granular datasets enables the researchers to potentially provide solutions that will ultimately lead to the provision of effective personalised medicine.

From their successful track record and experience, I believe Maria and Alyse have the ability to create a startup that has the potential to disrupt the current status quo in relation to the ownership of, the use of, and the ongoing access to a patient's genomic data.